Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…
As we approach year three of the COVID-19 pandemic, I am tired. I’m sure we all are. This pandemic fatigue, combined with the January blues, makes it a difficult time of year for many, and leaves the world feeling heavy and dark. While there is no immediate fix, being…
Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…
My plan for the holidays was to binge-watch all the Rocky movies. I love this character as played by Sylvester Stallone, and I can relate to how much he struggles to find his way through what life has thrown at him. I particularly identify…
“Every day is a new adventure!” This is often my response when someone asks how I’m doing. It also seems appropriate when looking forward to what 2022 may hold for me. I faithfully use my calendar to keep track of many tasks, both professional and personal. Before I was…
Lab-made versions of naturally occurring forms of nitro oleic acid effectively treated established pulmonary fibrosis (PF) in a mouse model, a study reports. These findings support the further development of these agents for reversing fibrosis, or tissue scarring, in the lungs and other organs, its scientists noted. The study,…
About half of the healthy older adults given PureTech’s anti-fibrotic therapy LYT-100 (deupirfenidone) were less likely to report gastrointestinal (GI) side effects compared with those given Esbriet (pirfenidone), according to a recent crossover study. Based on these findings, data to date from LYT-100’s clinical program and regulatory feedback, the…
MannKind Corporation has extended its collaboration with Thirona Bio to continue work toward an inhaled therapy for fibrotic diseases affecting the lungs, including idiopathic pulmonary fibrosis (IPF). Under a collaboration established last year, the companies are evaluating the therapeutic potential of FBM5712, an investigational medicine designed to…
If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…
I thought I understood the role of a caregiver. It was based on what I learned and observed watching others. It turns out I did not fully appreciate the role until I had a caregiver. The role of the caregiver is not a single responsibility, but a collection of…
Get regular updates to your inbox.
